Navigation Links
Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds
Date:2/25/2009

SAN DIEGO and MONTREAL, Feb. 25 /PRNewswire/ -- Speid & Associates, an international regulatory and drug development consultancy firm today announced that it has entered into a partnership with Genizon BioSciences to increase success rates of new drug compounds using Genizon's proprietary genetic platform. In this challenging economic climate in which innovative pharmaceutical and biotechnology companies have to watch every dollar that is spent on drug development, the Genizon and Speid collaboration will help to increase the ultimate success of drug development programs. Genizon's predictive techniques will also enable Speid's clients to identify and eliminate compounds with relatively low chances of success earlier than if these techniques are not used.

"As we develop effective regulatory strategies for our clients' drug candidates, I am very pleased that Genizon will work alongside us at our clients' requests," said Lorna Speid, Ph.D., president of Speid & Associates. Dr. Speid added, "I anticipate that the Genizon technology and expertise will allow our clients to re-visit compounds that may have been placed on the 'back-burner', but which may hold promise as new medications."

"We believe that we can add significant value to Speid & Associates' clients through pharmacogenomic studies and analyses using our gene discovery platform and expertise. These enable invaluable insights into drug response, and therefore improve clinical trial outcomes," said Majid Belouchi, Ph.D., founder and chief scientific officer of Genizon. He added, "We use predictive biomarkers to identify patients who are more likely to respond to a given treatment. Consequently, the combination of Genizon's proprietary gene discovery platform and Speid's expertise in regulatory affairs will assure expeditious pathways to commercialization."

About Genizon BioSciences

Genizon BioSciences Inc. is a leader in genetic solutions. Genizon discovers genes, genetic biomarkers, biochemical pathways and drug targets that are involved in human disease susceptibility and drug response. These genetic insights allow the development of predictive diagnostics that facilitate personalized medicine. Working with a network of over 1,000 clinical investigators, Genizon has recruited over 47,000 subjects in 25 common diseases, which are analyzed in a unique, integrated high throughput facility that is compliant with GCP and GLP guidelines. Discoveries are translated into clinical practice through collaborative research with academic and clinical leaders. Genizon also provides high throughput, high quality SNP genotyping, genetic analysis, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.

For more information visit: www.genizon.com

About Speid & Associates, Inc.

Speid & Associates, Inc. is a privately held regulatory affairs and drug development consultancy based in San Diego, California. Speid & Associates assists life science companies move new chemical entities to the finish line expeditiously by developing effective global regulatory strategies for the international pharmaceutical and biotechnology industries. Speid also conducts due diligence for investors and companies.

For more information visit: www.drugstomarket.com


'/>"/>
SOURCE Genizon BioSciences Inc.; Speid & Associates, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
5. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
8. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
9. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
10. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
11. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
Breaking Biology News(10 mins):